Don’t miss out - Get your tickets early!

Join this FREE, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Join this FREE WEBINAR presented by Dr Reid Robison (USA), Psychiatrist, Researcher & Chief Medical Officer, Novamind.

This webinar will cover the following topics:

Overview of psychedelic-psychotherapy as a promising new treatment option for eating disorders which traditionally are difficult-to-treat
Overview of the Emotion-focused ketamine-assisted psychotherapy (EF-KAP) protocol for anorexia, including some preliminary results from an open label feasibility trial
Overview of Group-based ketamine-assisted psychotherapy (G-KAP) for eating disorders
Real-world evidence from clinic data supporting the use of ketamine and Spravato for eating disorders, including bulimia nervosa, anorexia nervosa, and binge-eating disorder
Review key components of the MAPS' MDMA-assisted psychotherapy protocol specifically for anorexia nervosa and binge-eating, including the importance of care-giver involvement.
Review the rationale for using psilocybin + an IFS therapy model for eating disorders

Topic: Psychedelic-assisted psychotherapy for eating disorders: Growing evidence and future directions

Date: Wednesday 28 September 2022

Time: 12:55pm for 1:00pm start – 2:15pm (incl Q&A) (AEST)

The presentation WILL BEGIN AT 1:00pm.

Location: Online. A link will be emailed to you with the viewing details

Don’t miss out - Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

More about the presenters

Dr Reid Robison

M.D., MBA
Psychiatrist, Researcher & Chief Medical Officer, Novamind

Reid Robison, MD MBA, is a Psychiatrist, Researcher & Chief Medical Officer at Novamind. He has led over 100 clinical trials in neuropsychiatry and co-directed the molecular genetics laboratory at the University of Utah Department of Psychiatry. Reid is co-founder at Cedar Psychiatry, and serves as Medical Director of Center for Change, a top Eating Disorder treatment program. He was the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. He was one of the first clinicians to use k. off label for depression in Utah and obtained his first grant to study k. in 2011. He also led the Utah site for the pivotal IV k. study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato (esketamine) via breakthrough therapy designation in 2019. Reid supervises & trains the k.-assisted psychotherapy practitioners at Cedar Psychiatry’s clinics across Utah, and to date has guided thousands of k. therapy journeys and, and hundreds of Spravato dosing sessions. As a social entrepreneur, Reid has built and sold a number of purpose-driven companies including Tute Genomics, a venture-backed personalized medicine startup that was acquired in 2016.

Reid is adjunct faculty at the University of Utah, Brigham Young University, and Utah Valley University, has served on numerous non-profit boards. He founded the Polizzi Free Clinic, to bring mental health to Utah’s uninsured, and most recently co-founded SCPTR, a psychedelic therapy & research non-profit. He currently volunteers as medical support and a psychedelic therapist at Ayahuasca retreats abroad, and often provides medical safety consultations to shamans, therapists and researchers working in psychedelic medicine. Reid continues to share his vision for personalized medicine whenever he gets the chance as you can see in his TEDx talk entitled “The Genome Revolution Begins with You.”

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.

Please click here to make a tax-deductible donation.

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.